Dergiler / Journal of the Turkish-German Gynecological Association / 2013 / Cilt: 14 - Sayı: 4

Is there a link between polycystic ovary syndrome and non-thyroidal illness syndrome?

Polikistik over sendromu ve tiroid dışı hastalık sendromu arasında bir bağlantı var mı?

Sayfa
216–220
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bulgular: PKOS hastalarında ve kontrol grubunda TSH düzeyinde (1.9±1.8 vs. 1.2 μIU/mL±0.9 μIU/mL, p>0.05) anlamlı fark yoktu.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Amaç: Bu çalışmanın amacı, polikistik over sendromu (PKOS) olan hastalarda tiroid dışı hastalık sendromunun (NTIS) sıklığını tespit et- mektir.
📊
Temel Bulgular & Veri:Gereç ve Yöntemler: PKOSlu 52 hasta 6 aylık bir dönemde bu ke- sitsel çalışmaya alındı.
💡
Sonuç & Katkı:Bulgular: PKOS hastalarında ve kontrol grubunda TSH düzeyinde (1.9±1.8 vs. 1.2 μIU/mL±0.9 μIU/mL, p>0.05) anlamlı fark yoktu.
🔬Tür:Araştırma Makalesi
📍Kapsam:2013 · 52 hasta
⚙️Değişkenler:Alan Parametreleri

Özet

Amaç: Bu çalışmanın amacı, polikistik over sendromu (PKOS) olan hastalarda tiroid dışı hastalık sendromunun (NTIS) sıklığını tespit et- mektir. Gereç ve Yöntemler: PKOSlu 52 hasta 6 aylık bir dönemde bu ke- sitsel çalışmaya alındı. Kontrol grubuna yaş uyumlu 68 gönüllü kadın dahil edildi. Serum serbest triyodotironin (sT3), serbest tiroksin (sT4), tiroid uyarıcı hormon (TSH), anti-tiroperoksidaz antikoru (anti-TPO Ab) ve anti-tiroglobulin antikoru (anti-Tg Ab ) ölçüldü. Bulgular: PKOS hastalarında ve kontrol grubunda TSH düzeyinde (1.9±1.8 vs. 1.2 μIU/mL±0.9 μIU/mL, p>0.05) anlamlı fark yoktu. Kont- rol grubunda serum sT3 ve sT4 düzeyleri PKOS hastalarınınkinden anlamlı olarak daha düşüktü (fT3: 2.7±0.3 pg/mL vs. 2.9±0.3 pg/mL, p=0.02; fT4: 1.0±0.1 ng/dL vs. 1.1±0.1 ng/dL, p=0.03). Hs-CRP (yük- sek hassas C-reaktif protein) ve sT4 arasında istatistiksel olarak an- lamlı ilişki gözlendi (r=0.245, p=0.015). Ancak NTIS iki grupta da göz- lenmedi. Sonuç: Tiroid fonksiyon bozuklukları PKOSta gözlenebilir ancak PKOS hastalarındaki inflamatuar duruma rağmen bu çalışmada NTIS tespit edilmedi. (J Turkish-German Gynecol Assoc 2013; 14: 216-20) Anahtar kelimeler:

Abstract

Objective: The aim of this study was to determine the frequencyof non-thyroidal illness syndrome (NTIS) in patients with polycysticovary syndrome (PCOS).Material and Methods: During a 6-month period, 52 patients withPCOS were recruited for this cross-sectional study. The control groupincluded 68 age-matched female volunteers. Serum free triiodothyro-nine (fT3), free thyroxine (fT4), thyroid stimulating hormone (TSH),anti-thyroperoxidase antibody (anti-TPO Ab), and anti-thyroglobulinantibody (anti-Tg Ab) were measured.Results: The TSH level in the PCOS patients and controls did not dif-fer significantly (1.9±1.2 μIU/mL vs. 1.8±0.9 μIU/mL, p>0.05). SerumfT3 and fT4 levels in the controls were significantly lower than thosein the PCOS patients (fT3: 2.7±0.3 pg/mL vs. 2.9±0.3 pg/mL, p=0.02;fT4: 1.0±0.1 ng/dL vs. 1.1±0.1 ng/dL, p=0.03). The Hs-CRP (high-sen-sitivity C-reactive protein) level in the PCOS patients was significantlyhigher than in the controls (3.5±4.9 mg/L vs. 1.7±2.7 mg/L, p=0.03).A statistically significant relationship was observed between Hs-CRPand fT4 (r=0.245, p=0.015). However, NTIS was not observed in ei-ther group.Conclusion: Thyroid function abnormalities could be observed inPCOS; however, NTIS was not noted in the present study despite theinflammatory state of the PCOS patients.(J Turkish-German Gynecol Assoc 2013; 14: 216-20)

🔖

Bu Makaleye Atıf Yap

ŞAHİN, M., KARAKÖSE, M., ÇAKAL, E., GİNİŞ, Z., DELİBAŞI, T., SAYKİ, M. A., TOPALOĞLU, O. (2022). Is there a link between polycystic ovary syndrome and non-thyroidal illness syndrome?. Journal of the Turkish-German Gynecological Association, Cilt: 14 - Sayı: 4, 216–220. https://ajindex.com/articles/567601

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999
  2. [CrossRef] Ehrmann DA, Bames RB, Rosenfild RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999
  3. [CrossRef] Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, et al. The cardiovascular risk of young women with polyc- ystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004
  4. [CrossRef] Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ova- rian syndrome and its association with plasma PAI-1 levels. Eur J Endocriol 2004
  5. [CrossRef] Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndro- me: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004
  6. [CrossRef] Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004
  7. [CrossRef] Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005
  8. [CrossRef] Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001
  9. [CrossRef] Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994
  10. [CrossRef] Wilson PW, Kannel WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999
  11. [CrossRef] Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004
  12. [CrossRef] Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA. White blood cell count and incidence of co